title: Clinical development of histone deacetylase inhibitor romidepsin.
abstract: Histone deactylase inhibitors have emerged as a promising epigenetic therapy for neoplasic indications. The US Food and Drug Administration granted approval to romidepsin for treatment of cutaneous T cell lymphoma (CTCL) in 2009. Phase I/II trials of romidepsin as monotherapy or hybird therapy have demonstrated substantial efficacy profoundly in CTCL and peripheral T-cell lymphoma and marginally in other hematogological malignancies and solid tumors, with a tolerable safety and toxicity profile. The current status of the clinical evaluation of romidepsin is detailed in the present contribution.
authors.affiliation: Department of Medicinal Chemistry, School of Pharmacy, Shandong University, Ji'nan, Shandong, China.
authors.forename: P
authors.initials: P
authors.lastname: Guan
authors.forename: H
authors.initials: H
authors.lastname: Fang
mesh_terms: D000903:Antibiotics, Antineoplastic; D056572:Histone Deacetylase Inhibitors / Q000627:therapeutic use; D006657:Histones; D006801:Humans; D016410:Lymphoma, T-Cell, Cutaneous
chemical_list: D000903:Antibiotics, Antineoplastic; D056572:Histone Deacetylase Inhibitors; D006657:Histones